Shilpa Medicare Ltd's Unit IV, Jadcherla, Telangana facility has received Health Canada GMP Approval

Shilpa Medicare Ltd's finished dosage form manufacturing facility, Unit IV, situated at Pharma SEZ, Jadcherla, Telangana has received Health Canada GMP approval for the inspection conducted from September 12, 2022 to September 16, 2022.

The facility is involved in manufacturing, packaging, labelling and testing of finished dosage forms (sterile injections and oral solids) for the treatment of cancer and adjuvant therapy. This GMP approval will allow the company for the commercial distribution of products in Canada and enable new application submissions to Health Canada.

This approval reaffirms the company's focused efforts to maintain the GMP status up to the standards of global regulatory authorities.

Shares of Shilpa Medicare Limited was last trading in BSE at Rs. 281.55 as compared to the previous close of Rs. 284.95. The total number of shares traded during the day was 6176 in over 418 trades.

The stock hit an intraday high of Rs. 286.00 and intraday low of 280.25. The net turnover during the day was Rs. 1751517.00.

Source : Equity Bulls

Keywords

ShilpaMedicare INE790G01031 Pharmaceuticals FinishedDosage ManufacturingFacility Unit4 PharmaSEZ Jadcherla Telangana